首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1524270

無虹膜治療市場- 依治療類型（藥物[眼藥水、藥膏]、手術[人工虹膜植入術、前房角切開術]）、類型（先天性[孤立性、WAGR 症候群、吉萊斯皮膚綜合症]、後天）、年齡層- 全球預測（2024 年 -第2032章

Aniridia Treatment Market - By Treatment Type (Medication [Eye Drop, Ointment], Surgery [Artificial Iris Implantation, Goniotomy]), Type (Congenital [Isolated, WAGR Syndrome, Gillespie Syndrome], Acquired), Age Group - Global Forecast (2024 - 2032)

出版日期: 2024年04月29日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於醫療保健支出不斷增加以及 RampD 的大量投資，預計 2024 年至 2032 年全球無虹膜治療市場規模的複合年成長率將達到 5.1%。不斷成長的財政支持正在推動創新療法和個人化治療方法的探索，以改善患者的治療效果。

隨著醫療保健支出的激增，人們不斷努力增強無虹膜症的診斷工具和治療選擇。此外，醫學研究人員、臨床醫生和藥物開發人員之間的合作將進一步加速新療法的發現，例如基因編輯技術和幹細胞療法。根據美國醫學會的數據，2022年美國醫療保健支出成長4.1%，達到4.5兆美元，即人均13,493美元。這一成長可能會增加無虹膜治療和研究項目進展的資金支持。

市場分為治療類型、類型、年齡層和地區。

以治療類型來看，從 2024 年到 2032 年，藥物領域的無虹膜治療行業預計將以顯著的速度成長。和角膜併發症。正在進行的研究正在幫助探索新的治療類型，包括基因療法和基於幹細胞的方法，以解決導致無虹膜的潛在基因突變。創新療法還可以改善視力結果並有可能阻止疾病進展。

後天無虹膜類型細分市場的無虹膜治療市場預計將從2024 年擴大到2032 年。併發症。人們迫切需要使用矯正鏡片和藥物來緩解眩光和視力下降等症狀。最近，對後天性無虹膜症的研究有助於制定適合個別患者需求的個人化治療計劃，同時最佳化治療效果以提高視覺舒適度和生活品質。

從地區來看，在基因檢測和旨在增強診斷和個性化治療方法的諮詢舉措的興起的推動下，歐洲無虹膜治療行業規模預計將在 2024 年至 2032 年間實現利潤豐厚的成長。這些努力正在為基因定序和生物標記研究等技術創新讓路，以便更好地了解無虹膜的遺傳基礎。解決無虹膜根本原因並為歐洲患者提供更有效的治療選擇的持續發展也將促進市場成長。

主要趨勢
藥物
- 類型
  - 眼藥水
  - 藥膏
  - 其他藥物類型
- 配銷通路
  - 醫院藥房
  - 零售藥局
  - 網路藥局
手術
- 手術類型
  - 角膜移植術
  - 人工虹膜植入術
  - 青光眼引流裝置
  - 小梁切除術
  - 房角切開術
  - 其他手術類型
- 最終用戶
  - 醫院
  - 專科診所
  - 門診手術中心
  - 其他最終用戶

第 6 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
先天性無虹膜
- 孤立性無虹膜
- WAGR症候群
- 吉萊斯皮症候群
後天無虹膜症

第 7 章：市場估計與預測：按年齡分類，2021 - 2032

主要趨勢
兒科
成人

第 8 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AbbVie Inc.
Bausch & Lomb Incorporated
F. Hoffmann-La Roche Ltd
HumanOptics AG
Johnson & Johnson Vision
MORCHER GmbH
Novartis AG
Ophtec
Pfizer Inc.
REPER-NN LTD.

簡介目錄

Product Code: 9264

Global Aniridia Treatment Market size is anticipated to record 5.1% CAGR from 2024 to 2032, due to rising healthcare expenditure along with significant R&D investments. Growing financial support is enabling the exploration of innovative therapies and personalized treatment approaches to improve patient outcomes.

With the surging healthcare spending, there are ongoing efforts for enhancing diagnostic tools and therapeutic options for aniridia. Moreover, the collaborations between medical researchers, clinicians, and pharmaceutical developers will further accelerate the discovery of novel treatments, such as gene editing technologies and stem cell therapies. According to American Medical Association, the health spending in the U.S. increased by 4.1% in 2022 to 4.5 trillion or 13,493 per capita. This rise may potentially bolster the funding for advancements in aniridia treatment and research initiatives.

The market is segmented into treatment type, type, age group, and region.

By treatment type, the aniridia treatment industry from the medication segment is estimated to rise at a significant rate from 2024 to 2032. This is due to increasing medication options, such as topical therapies and the use of off-label for managing symptoms, such as photophobia and corneal complications. Ongoing research is helping in exploring new treatment types including gene therapy and stem cell-based approaches for addressing the underlying genetic mutations that cause aniridia. Innovative therapies are also improving vision outcomes and potentially halting disease progression.

Aniridia treatment market from the acquired aniridia type segment is expected to expand from 2024 to 2032. This is propelled by the approaches in acquired aniridia treatment for managing symptoms and complications resulting from trauma, surgery, or other acquired causes. There is a surging need for therapies to alleviate symptoms, such as glare and decreased visual acuity using corrective lenses and medications. Lately, research into acquired aniridia is helping in developing personalized treatment plans tailored to individual patient needs while optimizing therapeutic efficacy to enhance visual comfort and quality of life.

Regionally, the Europe aniridia treatment industry size is projected to depict lucrative growth between 2024 and 2032, propelled by the rise in genetic testing and counseling initiatives for enhancing diagnosis and personalized treatment approaches. These efforts are making way for technological innovations like genetic sequencing and biomarker research to better understand the genetic basis of aniridia. Increasing developments, for addressing the root causes of aniridia and offering more effective treatment options for patients across Europe will also boost the market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence rate of aniridia
  - 3.2.1.2 Increasing awareness for rare diseases
  - 3.2.1.3 Growing R&D investment
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Medication
- 5.2.1 Type
  - 5.2.1.1 Eye drop
  - 5.2.1.2 Ointments
  - 5.2.1.3 Other medication types
- 5.2.2 Distribution channel
  - 5.2.2.1 Hospital pharmacies
  - 5.2.2.2 Retail pharmacies
  - 5.2.2.3 Online pharmacies
5.3 Surgery
- 5.3.1 Surgery type
  - 5.3.1.1 Keratoplasty
  - 5.3.1.2 Artificial iris implantation
  - 5.3.1.3 Glaucoma drainage devices
  - 5.3.1.4 Trabeculectomy
  - 5.3.1.5 Goniotomy
  - 5.3.1.6 Other surgery types
- 5.3.2 End-user
  - 5.3.2.1 Hospitals
  - 5.3.2.2 Specialty clinics
  - 5.3.2.3 Ambulatory surgical centers
  - 5.3.2.4 Other end-users

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Congenital aniridia
- 6.2.1 Isolated aniridia
- 6.2.2 WAGR syndrome
- 6.2.3 Gillespie syndrome
6.3 Acquired aniridia

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pediatric
7.3 Adult

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

9.1 AbbVie Inc.
9.2 Bausch & Lomb Incorporated
9.3 F. Hoffmann-La Roche Ltd
9.4 HumanOptics AG
9.5 Johnson & Johnson Vision
9.6 MORCHER GmbH
9.7 Novartis AG
9.8 Ophtec
9.9 Pfizer Inc.
9.10 REPER-NN LTD.

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

全球無虹膜治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

視障市場：按產品類型（教育設備/軟件、移動設備、低視力設備（智能眼鏡、VTS Link）、其他、最終用戶、地區 - 規模、份額、前景、機會分析，2023-2030 年）

FAQ